$CLVT

Clarivate earnings beat by $0.03, revenue fell short of estimates

Clarivate (CLVT) reported Q3 EPS of $0.21, beating estimates by $0.03, but revenue of $481.6M missed expectations of $566.77M. The company provided Q4 and FY 2026 guidance, with revenue and EPS estimates generally below analyst consensus. CLVT's stock is down 10.27% over 3 months and 52.30% over 12 months.

Original reporting
Published Nov 3, 2026, 11:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CLVT
Bearish
high confidence
Mentioned
$CLVT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CLVTBearishMed
01

Why it matters

The earnings release introduces new guidance that falls short of consensus, likely prompting a reassessment of valuation.

02

Market read

The earnings miss and lowered guidance could trigger a short‑term sell‑off in CLVT and influence peer sentiment.

03

What to watch

Potential cost‑cutting measures or upcoming contract wins not disclosed could mitigate the revenue shortfall.

Relevance 8/10Novelty 8/10Timing: today

Background

Clarivate (NYSE: CLVT) provides analytics and insights for research, with Q3 results released on Nov 3, 2026.

Company-level read

Ticker impact

$CLVTBearishHigh confidence
Context

Clarivate reported Q3 EPS beat but revenue miss and lowered Q4 guidance, a fresh earnings disclosure.

Expected impact

downward pressure as investors price in lower revenue and guidance

Evidence & confidence

The miss on revenue and reduced Q4 outlook are material for a data‑analytics firm, likely prompting sell‑offs.

Market effects

May weigh on other information‑services companies that rely on subscription revenue.

Limited to US‑listed tech sector, no broader regional effect.

Minimal global impact beyond sector peers.

Counterpoint

Some investors may view the EPS beat as a sign of pricing power despite revenue weakness.

Key entities

  • Clarivate

    Provider of analytics and insights, ticker CLVT.

Related articles

$CLVTMed

Clarivate Plc Q3 2026 Earnings Call Summary

Clarivate reported Q3 2026 earnings, highlighting 1.8% organic ACV growth and 300 basis points of adjusted EBITDA margin expansion. The company completed the Life Sciences & Healthcare divestiture, focusing on higher-quality, recurring revenue. Management expects Q4 2026 organic revenue growth to exceed 2% and targets 10-15% free cash flow growth in 2027. One-time transaction costs of $30 million were incurred, and free cash flow guidance was adjusted to $320M-$340M.

$CLVTHighAI 8/10

Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation — Improved recurring organic revenue growth driven by portfolio transformation and AI-led innovation — — Updates 2026 financial outlook following the divestiture of Life Sciences & Healthcare

$CLVTMed

Why is Clarivate stock sliding today?

Clarivate (CLVT) stock fell 5.4% in pre-market trading after Q3 2026 results beat EPS estimates ($0.21 vs. $0.18) but missed revenue forecasts by 16.7% ($481.6M vs. $566.77M), down 9.2% YoY. Full-year revenue guidance ($1.96B-$1.98B) also fell short of consensus ($2.20B). The miss was exacerbated by portfolio disposals and cautious forward outlook.